Etoposide—chemistry, preclinical and clinical pharmacology
- 30 June 1982
- journal article
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 9, 3-13
- https://doi.org/10.1016/s0305-7372(82)80072-8
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Model studies of etoposide resistanceCancer Treatment Reviews, 1982
- Teratogenic and cytogenetic effects of some plant‐derived antitumor agents (vincristine, colchicine, maytansine, VP‐16‐213 and VM‐26) in miceTeratology, 1978
- Multicompartment Pharmacokinetic Model of 4′-Demethylepipodophyllotoxin 9-(4,6-O-Ethylidene- β-D-glucopyranoside) in HumansJournal of Pharmaceutical Sciences, 1978
- Cell cycle stage-dependent induction of G2 phase arrest by different antitumor agentsPublished by Elsevier ,1978
- Effects of podophyllotoxin and VP-16-213 on microtubule assembly in vitro and nucleoside transport in HeLa cellsBiochemistry, 1976
- Delayed toxicity of epipodophyllotoxin derivatives (VM 26 and VP 16-213), due to a local effectPublished by Elsevier ,1976
- Combination chemotherapy with 4′Demethylepipodophyllotoxin 9-(4,6-0-ethylidene-β-d-glucopyranoside), VP 16–213 (NSC 141540) in L1210 LeukemiaPublished by Elsevier ,1976
- Comparison of the human pharmacokinetics of VM-26 and VP-16, two antineoplastic epipodophyllotoxin glucopyranoside derivativesPublished by Elsevier ,1975
- Response of L1210 to combinations of cytosine arabinoside and VM-26 or VP16-213Published by Elsevier ,1975
- Activity of a new glycosidic lignan derivative (VP 16-213) related to podophyllotoxin in experimental tumorsPublished by Elsevier ,1973